Scedosporium prolificans（S. prolificans）is a type of mold, which rarely affects immunocompromised people. We treated a 71-year-old woman with acute myeloid leukemia（AML-M5a）with low-dose cytarabine, acralubicin, and filgrastim as the induction therapy. On day 7 after the initiation of chemotherapy, she became febrile and agranulocytic, and developed anal pain; therefore, we discontinued the chemotherapy on day 8. Broad-spectrum antibiotics, micafungin, and then liposomal amphotericin B were ineffective. The serum concentration of β-D-glucan was 525 pg/mL. She died of multiple organ failure on day 17. S. prolificans was detected from the blood culture on day 13. Physicians should consider Scedosporium spp. infection when principal antifungal agents are ineffective and fungal infection is strongly suspected.
Introduction
Scedosporium species（spp.）are ubiquitous fungi, distributed in living environments such as polluted water and soil, and classified as ascomycota in a group of molds 1） . Scedosporium spp. consist of 2 species: Scedosporium prolificans（S. proloficans）and S. apiospermum. S. prolificans was first revealed to be pathogenic in 1984, although the incidence of infection is very low, with 1.33 affected cases per 100,000 people in the United States 1,2） . S. prolificans mostly affects immunocompromised people, such as patients with hematologic diseases 3） . Human infection often results from the inhalation of spores present in the environment into the lungs or paranasal sinuses, or through direct inoculation, such as in skin puncture 4） . S. prolificans-affected body regions include the blood, lungs, bones, and soft tissue, and S. prolificans disseminates to multiple organs in many cases. Although rare, S. prolificans infection often causes fatal disease; disseminated disease is particularly associated with a high mortality rate of 87.5% 5） , because active antifungal agents against S. prolificans are currently not available. Here, we report a patient with acute myeloid leukemia（AML）who developed fatal fungemia with S. prolificans during induction chemotherapy for AML.
Case report
A 71-year-old woman with leukopenia was admitted to our hospital because of suspected AML. Three years before admission, she had been diagnosed with rheumatoid arthritis（RA）and Sjögren s syndrome. Two years before admission, she had been treated with tocilizumab（8 mg/kg, weekly）for the acute exacerbation of RA, with improvement of the disease. Two months before admission, she had developed leukopenia（white cell count: 1.8×10 9 /L） . Therefore, tocilizumab was discontinued with persistent leukopenia, and a bone marrow aspirate led to suspected AML. Thus, she was referred to our hospital.
Physical and physiological examinations on admission were unremarkable. Laboratory findings on admission are shown in She had a history of tocilizumab therapy, and was thereby suggested to be in an immunocompromised state. We, therefore, employed CAG chemotherapy（low-dose cytarabine, acralubicin, and filgrastim）as remission induction therapy for AML. The clinical course of the patient is shown in Fig. 2 . On day 7 after the initiation of CAG therapy, she developed anal pain due to an exacerbated hemorrhoid with fever above 38℃. The hemorrhoid was swollen, reddish, and partially erosive and hemorrhagic. The WBC count was 0.5×10 9 /L wih 0% neutrophils. We administered tazobactam/piperacillin for the infectious hemorrhoid, which brought about transient resolution of the fever. On day 8, we discontinued the CAG because of agranulocytosis and a clearly infectious portion of the painful hemorrhoid. On day 11, she again became febrile with a body temperature of 38℃ or higher; therefore, we added vancomycin for possible infection caused by methicillin-resistant Staphylococcus aureus. On day 12, blood culture yielded Enterococcus faecium which was susceptible to vancomycin, while the culture of viscous fluid taken by swabbing from the erosive portion of the painful hemorrhoid yielded a negative result. On day 13, however, she became more febrile and developed frequent diarrhea with abdominal tenderness in addition to the anal pain. We, therefore, added micafungin for possible intestinal candidiasis presumably derived from the infectious hemorrhoid. On day 14, she had a persistently high fever with peritoneal irritation sign, and a laboratory test showed that the serum concentration of β-D-glucan had elevated to 525 pg/mL（normally below 11 pg/mL） . From this time-point, she became drowsy, with a progressive deterioration of consciousness. Although we subsequently obtained negative results from repeated blood cultures, we changed micafungin to liposomal amphotericin B and tazobactam/ piperacillin to meropenem for possible infections by micafungin-resistant fungi or multiple-drug-resistant bacteria, without improvement of her condition. She developed multiple organ failure and died on day 17. Autopsy was not performed. The day after her death, we received a report that a fungus had been grown from blood culture with a culture bottle（BACTEC Aerobic Plus, but not BACTEC Anaerobic Plus; Nippon Becton Dickinson Co., Ltd., Tokyo, Japan） , which was performed on day 13. The fungus was also grown from fecal culture performed on day 15, and blood cultures performed on days 14 and 15. Gram-staining of the pathogens from the blood culture is shown in Fig 3A. Morphologically, the fungus had mold-like features, although we could not identify the exact fungal species at that time. The growth pattern of the fungus in BD difco Potato Dextrose Agar（Nippon Becton Dickinson Co., Ltd., Tokyo, Japan）is shown in Fig. 3B . The color of the fungus colony was blackish to light brown, and it was covered with whitish filamentous organisms. On cellophane tape preparation, Scedosporium spp. was suspected because of the characteristic feature of the hyphae （Fig. 3C） . A few weeks later, this fungus was identified as S. prolificans by rRNA sequence analysis 
Discussion
S. prolificans infection is rare, as previously described. However in the past 5 years, 16 cases of S. prolificans infection have been reported 8−23） . As shown in Table 2 , the majority of these 16 patients were immunocompromised, having hematologic diseases such as myeloid leukemia. These immunocompromised patients had a poor prognosis, while patients without hematologic or immunologic disorders had a favorable one, with the exception of 2 cases 12, 23） . Interestingly, one of these 2 patients was a drowning 5 victim in the tsunami of the Great East Japan Earthquake in 2011, indicating the presence of S. prolificans in muddy water or soil.
In the present patient, we employed low-intensi- C: On cellophane tape preparation, the hyphae had a septum, and the conidium was ovum-shaped, slightly narrowing near the apex, which resulted in the formation of a small apical mass（lactophenol cotton blue staining, ×200） .
ty chemotherapy（CAG chemotherapy）under the assumption that she was potentially immunocompromised because of her history of tocilizumub therapy for RA. Nevertheless, she became agranulocytic on day 7 after the initiation of CAG chemotherapy, and subsequently developed bacteremia with Enterococcus faecium and finally fungemia with S. prolificans. This clinical course is quite exceptional with induction chemotherapy for AML with a low-intensity protocol. Regarding tocilizumab therapy for RA, a large cohort study in Japan was published 24） . In this report, the most common adverse events were infections, including bacterial pneumonia, sepsis, and viral infection, indicating that RA patients treated with tocilizumab have a risk of infections. Furthermore, 3 risk factors were identified: a history of lung disease, prednisolone administration at 5 mg/day or more, and an age of 65 or older. Although the present patient had 2 of these 3 risk factors, it is difficult to fully explain her unfavorable clinical course with the risk of infection by tocilizumab.
We performed antibiotic and antifungal therapies according to guidelines for febrile neut- , as well as in the present patient.
Regarding the route or origin of S. prolificans infection in the present patient, the infectious hemorrhoid is a possibility because the anal pain persisted throughout the course with fever, although S. prolificans was not detected on culture of the swollen and erosive hemorrhoid. Aside from the origin of S. prolificans infection, S. prolificans might have emerged as a microbial substitute after the treatment for bacteremia with vancomycin-susceptible Enterococcus faecium.
As for the treatment of S. prolificans infection, few effective anti-fungal agents are currently available when compared to those for S. apiospermumas, as shown in Table 3 . However, voriconazole may be useful in some cases of S. prolificans infection based on its minimum inhibitory concentration（MIC）against S. prolificans. Furthermore, the combination of voriconazole and terbinafine has been widely used and brought about favorable outcomes for immunocompetent but not immunocompromised patients, as shown in Table  2 . Indeed, in an in vitro study, the combination of terbinafine and azole antifungal agents or that of amphotericin B and pentamidine exhibited some activities against S. prolificans
26）
. Therefore, the identification of an effective combination of antifungal agents using a checkerboard titration method 26） may be useful. Furthermore, the early diagnosis of S. prolificans infection and prompt initiation of effective antifungal treatment including voriconazole, either as monotherapy or combination therapy, appear to be crucial for immunocompromised patients. 
